Search the Newsreel

BrightView Holdings (BV) Misses Q3 Earnings and Revenue Estimates

BrightView Holdings (BV) reported Q3 earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.28, and revenues of $717.6 million, also below estimates. This marks the third time in four quarters the company has missed EPS expectations. Despite underperforming the market year-to-date, …

Viemed Healthcare, Inc. (VMD) Stock Price, News, Quote & History

This page provides a comprehensive overview of Viemed Healthcare, Inc. (VMD) stock, including its current price, recent news headlines, and historical performance data. The stock closed at $9.73 on August 7 and has shown positive year-to-date and one-year returns, outperforming the S&P 500 in …

Arrowstreet Capital Limited Partnership Purchases New Holdings in Avient Corporation $AVNT

Arrowstreet Capital Limited Partnership recently acquired 87,261 shares of Avient Corporation, valued at approximately $3.17 million, establishing a 0.10% stake in the company. Institutional investors now collectively own 95.48% of Avient. The company maintains a "Moderate Buy" consensus rating from analysts with an average …

Is Avient (AVNT) Still Undervalued With A 37% Fair Value Gap?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Avient stock has gained 20.4% year to date, yet the latest valuation checks and an intrinsic value estimate based on a Discounted Cash Flow (DCF) …

TeamViewer Aktie: Gewinn steigt auf 64,3 Millionen Euro

Why BrightView Holdings Stock Tanked Today

BrightView Holdings (NYSE: BV) stock got smacked with an investor sell-off on Tuesday. The catalyst was the company's fiscal third-quarter results, which, despite a guidance raise for a key line item, missed analyst estimates for both revenue and profitability. Two metrics, two different trajectories …

AbbVie (ABBV) Wins FDA Review For BOTOX Cosmetic In Jawline Treatment Push

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Allergan Aesthetics, an AbbVie company, reported that the FDA has accepted for review a supplemental Biologics License Application for BOTOX Cosmetic to treat …

Navient (NAVI) Q2 Earnings: What To Expect

Shareholders Will Be Pleased With The Quality of Country View Berhad's (KLSE:CVIEW) Earnings

Earnings call transcript: Viemed Healthcare Q2 2026 profit miss sends shares down 17%

Viemed Healthcare reported mixed Q2 2026 results, with revenue slightly exceeding estimates but earnings falling short, causing a 17% stock drop. The company achieved record revenue of $78.1 million and its highest-ever active ventilator patients, driven by growth across its ventilator, sleep, resupply, and …

Viemed Healthcare Misses Q2 2026 EPS by 41.7%, Surging Revenue

Viemed Healthcare (NASDAQ:VMD) reported Q2 2026 diluted earnings of $0.07 per share, significantly missing the $0.12 consensus estimate by 41.7%. Despite this, the company saw strong revenue growth, with $78.1 million representing a 23.9% increase year-over-year. The shortfall in earnings, alongside operational expansion serving …

Brightview Holdings Inc reports results for the quarter ended June 30 - Earnings Summary

Brightview Holdings Inc has released its earnings summary for the quarter that ended on June 30. The report details the company's financial performance during this period.

BrightView Reports Third Quarter Fiscal 2026 Results With Second Consecutive Quarter of Land Maintenance Revenue Growth

AbbVie Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

This article analyzes AbbVie Inc.'s recent earnings beat and the subsequent adjustments made by financial analysts to their future predictions. It will likely cover the company's financial performance, the reasons behind the beat, and how these updated analyst ratings might affect investor sentiment and …

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

AbbVie Inc. has initiated a $10 billion bond sale to finance its acquisition of Apogee Therapeutics, as reported by Bloomberg and MT Newswires. This move comes alongside several other recent news items for AbbVie, including positive recommendations for Ubrelvy reimbursement in Canada and FDA …

Gator Financial Partners Q2 2026 Commentary

Gator Financial Partners released their Q2 2026 commentary, detailing strong absolute and decent relative performance for their funds. The letter highlighted their investment thesis on Navient Corporation (NAVI), arguing it is undervalued due to a misperception of its future as a growth lender, especially …

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset

ABBV Q2 Deep Dive: Immunology and Neuroscience Expansion Shape Outlook Amid Guidance Reset Pharmaceutical company AbbVie (NYSE:ABBV) reported Q2 CY2026 results exceeding the market's revenue expectations , with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share …

AbbVie (ABBV) Lifted Guidance, Has The Market Already Priced It In?

AbbVie Seeks at Least $8 Billion in Debt to Fund Apogee Deal

AbbVie Inc. is reportedly looking to raise at least $8 billion, and potentially up to $10 billion, through an investment-grade bond offering. The pharmaceutical giant intends to use these funds to finance a portion of its acquisition of Apogee Therapeutics Inc. The final size …

Guggenheim Adjusts Price Target on AbbVie to $288 From $261, Maintains Buy Rating

Guggenheim has increased its price target for AbbVie (NYSE: ABBV) to $288 from $261, while reiterating a Buy rating on the stock. This adjustment comes amidst other analyst revisions for AbbVie, with Rothschild & Co Redburn also adjusting its target to $285 and Oppenheimer …

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

If approved, BOTOX®Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle …

Trading the Move, Not the Narrative: (SUPV) Edition

This article provides an AI-generated analysis for Grupo Supervielle S.a. (NASDAQ: SUPV), highlighting a neutral sentiment across all time horizons and an exceptional risk-reward short setup. It details three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop loss …

Grupo Supervielle (NYSE:SUPV) Share Price Passes Below 50-Day Moving Average - Should You Sell?

Grupo Supervielle (NYSE:SUPV) shares have fallen below their 50-day moving average, trading as low as $9.34 compared to the $9.85 average. Despite this technical weakness, several major institutional investors, including PointState Capital and Goldman Sachs, have increased their positions in the company. Analyst sentiment …

Vietnam Electricity Construction Joint Stock Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment

UBRELVY®(ubrogepant) positive recommendation by Canada's Drug Agency (CDA-AMC)is supported by evidence from the pivotal Phase 3 ACHIEVE I and ACHIEVE II studies. CDA-AMC recommendation recognizes the need for additional migraine-specific acute treatment options for adults. Migraine affects an estimated 5 million Canadians with the …

Edgestream Partners L.P. Has $1.74 Million Position in Avient Corporation $AVNT

Edgestream Partners L.P. significantly increased its stake in Avient Corporation (NYSE:AVNT) by 361.4% in the first quarter, now holding 47,958 shares valued at approximately $1.74 million. Institutional investors and hedge funds collectively own 95.48% of the stock. Avient exceeded Q1 earnings expectations and maintains …

VinaCapital Vietnam Opportunity Fund boosts treasury through share buyback

UFO Moviez India Ltd ad revenue surges 33%, net debtors fall

BrightView (NYSE:BV) Misses Q2 CY2026 Sales Expectations, Stock Drops

BrightView (BV) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Viemed Healthcare, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:VMD) 2026-08-04

Viemed Healthcare, Inc. announced record-setting Q2 2026 financial results, with net revenues of $78.1 million, a 23.9% increase year-over-year. The company also reported an increase in ventilator patients to 12,635 and PAP therapy patients to 37,825. Due to strong performance, Viemed has updated its …

ClearView Wealth (ASX:CVW) Sets a Five-Cent Payout Before the Zurich Deal

Does Viemed Healthcare Inc (VMD) Justify Its 6.2% Overvaluation

Viemed Healthcare Inc (VMD) reported strong Q2 2026 financial results with net revenues of $78.1 million, a 23.9% increase year-over-year, and significant growth in patient numbers for ventilator and PAP therapy. Despite this growth, net income and Adjusted EBITDA saw declines, and the stock …

Viemed Healthcare (NASDAQ:VMD) Releases Quarterly Earnings Results, Misses Estimates By $0.05 EPS

Viemed Healthcare, Inc. (VMD) reported Q2 earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.10. Despite this earnings miss, the company's revenues of $78.1 million surpassed estimates and showed growth from the prior year. The stock has outperformed the S&P 500 …

Lazard Asset Management LLC Increases Position in Viemed Healthcare, Inc. $VMD

Lazard Asset Management LLC significantly increased its stake in Viemed Healthcare, Inc. (NASDAQ:VMD) during the first quarter, adding 116,700 shares to own 215,938 shares valued at approximately $1.99 million. Despite this, Viemed Healthcare reported quarterly earnings per share of $0.06, missing the consensus forecast …

Viemed Healthcare (Nasdaq: VMD) lifts Q2 revenue 23.9% on growth

Viemed Healthcare (VMD) reported a 23.9% increase in Q2 2026 revenue, reaching $78.1 million, driven by growth in ventilator rentals, other home medical equipment, and equipment and supply sales, including contributions from the Lehan Drugs acquisition. Despite the revenue growth, net income attributable to …